Zerumbone Suppresses Human Colorectal Cancer Invasion and Metastasis via Modulation of FAk/PI3k/NFκB-uPA Pathway.


Journal

Nutrition and cancer
ISSN: 1532-7914
Titre abrégé: Nutr Cancer
Pays: United States
ID NLM: 7905040

Informations de publication

Date de publication:
2019
Historique:
pubmed: 18 1 2019
medline: 2 5 2020
entrez: 18 1 2019
Statut: ppublish

Résumé

The current study explored the basic molecular mechanisms of zerumbone (ZER), an herbal compound, in inhibiting the migration and invasion of colorectal cancer (CRC) cells in vitro. Two types of CRC cells, namely HCT-116 and SW48, were treated with various concentrations of ZER (8, 16, and 24 µM) for 24, 48, and 72 h, respectively. In vitro assays were performed to determine alterations in proliferation ability, mRNA expression and protein levels, and migration and invasion potential of CRC cells. An SYBR Green-based quantitative polymerase chain reaction (PCR) was utilized to detect the gene expression of focal adhesion kinase (FAK), nuclear factor (NF)-κB, and urokinase-type plasminogen activator (uPA) followed by the evaluation of the level of proteins by western blotting. Migration and invasion potentials of HCT-116 and SW48 cells treated by ZER were examined using migration and invasion assay kits, respectively. We compared the results of all experiments with control groups, including FAK inhibitor, ZER + FAK inhibitor-treated cells, NF-β inhibitor, ZER + NF-β inhibitor, and untreated cells. The data in the present study suggest that ZER may exert its antimetastatic effects through inhibition of FAk/PI3k/NF-κB-uPA signaling pathway, thereby possibly representing a novel class of FAK inhibitors.

Identifiants

pubmed: 30650987
doi: 10.1080/01635581.2018.1540719
doi:

Substances chimiques

NF-kappa B 0
Phosphoinositide-3 Kinase Inhibitors 0
Sesquiterpenes 0
zerumbone 471-05-6
Focal Adhesion Protein-Tyrosine Kinases EC 2.7.10.2
Urokinase-Type Plasminogen Activator EC 3.4.21.73

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

159-171

Auteurs

Narges Hosseini (N)

a Research Center for Molecular Medicine , Hamadan University of Medical Sciences , Hamadan , Iran.

Amineh Khoshnazar (A)

a Research Center for Molecular Medicine , Hamadan University of Medical Sciences , Hamadan , Iran.

Massoud Saidijam (M)

a Research Center for Molecular Medicine , Hamadan University of Medical Sciences , Hamadan , Iran.

Farid Azizi Jalilian (F)

b Microbiology Department, Faculty of Medicine , Hamadan University of Medical Sciences , Hamadan , Iran.

Rezvan Najafi (R)

a Research Center for Molecular Medicine , Hamadan University of Medical Sciences , Hamadan , Iran.

Ali Mahdavinezhad (A)

a Research Center for Molecular Medicine , Hamadan University of Medical Sciences , Hamadan , Iran.

Razie Ezati (R)

c Institute of Medical Biotechnology , National Institute of Genetic Engineering and Biotechnology , Tehran , Iran.

Alireza Sotanian (A)

d Modeling of Noncommunicable Disease Research Center , School of Public Health, Hamadan University of Medical Sciences , Hamadan , Iran.

Razieh Amini (R)

a Research Center for Molecular Medicine , Hamadan University of Medical Sciences , Hamadan , Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH